Study of RP-001 for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an investigational drug called RP-001 in people with advanced solid tumors. It aims to see if RP-001 can help when given alone, especially in cancers that may respond to a class of chemotherapy called taxanes, or in pancreatic or colorectal cancer that has returned or not responded to prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with advanced or metastatic cancer.
- Your tumor can be measured on scans according to standard criteria.
- You have not had an active infection needing treatment in the last 28 days.
- You do not have serious heart problems (like recent heart attack, heart failure, or irregular heartbeat).
- You are not pregnant or breastfeeding, and you are not receiving other cancer treatments (except a specific hormone therapy).
- If your cancer has spread to the brain, it must have been treated and stable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
This trial is testing a new drug called AST-001 for people with advanced solid tumors (including pancreatic cancer) that have not responded to standard treatments. The study aims to find the right dose and see how well the drug works.
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This study tests an investigational drug (RR001) given after chemotherapy for people with locally advanced pancreatic cancer that hasn't spread. It aims to see if the new treatment is safe and may help shrink tumors that can be reached with a needle injection.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This study tests a new medicine called IPN01195 for adults with advanced solid tumors that have a specific genetic change (MAPK pathway). It aims to see if the drug is safe and works against these cancers when other treatments are no longer working.
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.